NCT06702995
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
At risk: Primary completion moved 1 year 2 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion dates pushed to Jul 13, 2027
- Eligibility criteria expanded, about 40 words
- Primary endpoints: details revised at 2 of 3 entries
- Secondary endpoints: details revised at 7 of 12 entries
- Minor Trial status: Enrolling by Invitation to Recruiting
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Ph Ib/IIa: Overall safety profile including adverse events
Timeframe: Baseline up to approximately 2 years
Ph Ib/IIa: Recommended phase 2 doses (RP2D) of XNW5004 in combination with enzalutamide
Timeframe: Approximately 6 months
Preliminary efficacy determination as evaluated by disease specific response criteria
Timeframe: Baseline until disease progression or death or through study completion (approximately 2 years)
Secondary (9)
Ph Ib/IIa: Pharmacokinetic Parameters
Ph Ib: Pharmacodynamic Parameters
Overall Response Rate (ORR)
Disease Control Rate (DCR)
Evaluate overall survival
Show 4 moreShow less
Proportion of patients with a PSA response at week 12
Prostate-specific Antigen 50 (PSA50) Response
Time to first symptomatic skeletal event (SSE)
Ph IIb:Overall safety profile including adverse events
Arms and interventions
Phase IbExperimental
Participants with mCRPC will receive XNW5004 at escalating dose levels in combination with enzalutamide.
Phase IIaExperimental
Participants with mCRPC will receive XNW5004 in combination with enzalutamide.
Phase IIbExperimental
Participants with mCRPC will receive XNW5004 in combination with enzalutamide or enzalutamide alone
Drugs: XNW5004, enzalutamide
Sites
2 sites in 1 country